- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00201942
PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)
A Prospective Study to Determine the Role of 2-[18F]Fluoro-2-Deoxy-D-Glucose (FDG)Positron Emission Tomography (PET)in the Assessment of Regional Nodal Spread of Disease in Breast Cancer Patients
The overall goal of this study is to determine how FDG-PET can be incorporated into the assessment of the axilla in the staging and treatment of women with early stage breast cancer.
A multicentre, prospective, diagnostic accuracy study will be conducted evaluating the ability of positronic emission tomography using fluorodeoxyglucose (FDG-PET) to detect the presence or absence of axillary lymph node metastases in newly diagnosed breast cancer patients with no clinical evidence of spread of disease beyond the breast.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 1C3
- Juravinski Cancer Centre
-
Hamilton, Ontario, Canada, L8N 4A6
- St. Joseph's
-
Kingston, Ontario, Canada, K7L 5P9
- Kingston Regional Cancer Centre
-
London, Ontario, Canada, N6A 4L6
- London Regional Cancer Centre
-
Ottawa, Ontario, Canada, K1Y 4K7
- Ottawa Regional Cancer Centre
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Hospital
-
Toronto, Ontario, Canada, M5G 1X5
- Mount Sinai Hospital
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's
-
Toronto, Ontario, Canada, M2J 1V1
- North York
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Regional Cancer Centre and Women's College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologic diagnosis of invasive breast cancer,
- Resectable primary cancer.
Exclusion Criteria:
- The diagnosis of invasive breast cancer was made more than 3 months prior to registration,
- Patient and/or surgeon are not willing to proceed with a SNB or AND after the PET scan is completed,
- Patient and/or surgeon are not willing to proceed with a level I and II AND if the SNB is positive, if the PET scan shows increased uptake in the ipsilateral axilla, or if the surgeon is still gaining experience in the performance of SNB,
- SNB or AND has already been done,
- Chemotherapy has been given or will be given prior to PET scan or SNB or AND,
- Significant serious concurrent medical problems (e.g., uncontrolled diabetes),
- Patient is pregnant or lactating,
- Patient is unable to lie supine and with both arms above their heads for PET scan,
- Known hypersensitivity to FDG,
- Clinical evidence of regional nodal metastases (fixed, matted axillary nodes),
- Clinical evidence of distant metastases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
The primary outcomes are the sensitivity and specificity of FDG-PET in axillary node assessments using axillary node assessment [Sentinel Node Biopsy(SNB) with or without Axillary Node Dissection (AND)] as the reference standard.
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Patients with positive FDG-PET in non-axillary nodal areas;
|
|
Patients with positive FDG-PET in other non-nodal areas;
|
|
Patients with positive FDG-PET in the residual breast tissue.
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Kathleen Pritchard, MD, Sunnybrook Regional Cancer Centre
- Principal Investigator: Claire Holloway, MD, Sunnybrook Regional Cancer Centre
- Principal Investigator: David McCready, MD, Princess Margaret Hospital, Canada
- Principal Investigator: Jim Julian, M.Math., McMaster University
- Principal Investigator: Mark N Levine, MD, Ontario Clinical Oncology Group (OCOG)
- Principal Investigator: Wendy Shelley, MD, Kingston Regional Cancer Centre
- Principal Investigator: Karen Gulenchyn, MD, PhD, McMaster University
- Principal Investigator: Frances O'Malley, MD, Mount Sinai Hospital
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTA-Control-092493
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.